Gubra: Q1 2026 trading statement, pipeline momentum offsets softer CRO outlook
Analytikerkommentar af

Gubra: Q1 2026 trading statement, pipeline momentum offsets softer CRO outlook

Gubra delivered its Q1 2026 trading statement yesterday, and the headlines are dominated by Biotech progress: AbbVie's ABBV-295 MAD data (~10% weight loss in 12-13 weeks, with comparable efficacy on every-other-week and monthly dosing) and the BI 3034701 triple agonist are both confirmed for Phase 2 entry in 2026, Q3 and mid-year, respectively. 

Columbus: Soft start to 2026 - guidance maintained on improving momentum
Analytikerkommentar af

Columbus: Soft start to 2026 - guidance maintained on improving momentum

This morning, Columbus released its Q1 2026 Interim Report. Performance for the quarter was below expectations, with revenue of DKK 418m corresponding to a 4% decline, and EBITDA of DKK 26m translating into a margin of 6.3% (Q1 2025: 10.7%). The earnings development primarily reflects a slow start to the year, particularly in January, with weaker-than-expected contribution margins across the Business Lines.

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer